Calidi Biotherapeutics Inc. has appointed Dr. Eric Poma as its new Chief Executive Officer and board member, marking a significant leadership transition for the biotechnology company. Poma brings more than 30 years of experience in the life sciences sector to his new role, succeeding Allan Camaisa, who will continue to serve on the board.
The appointment highlights the company's strategic focus on leveraging experienced leadership to drive innovation in cancer therapies. With extensive industry knowledge, Dr. Poma is expected to play a crucial role in developing and advancing Calidi's proprietary groundbreaking therapeutic approaches.
Research suggests that companies with strong leadership are 2.3 times more likely to outperform their competitors financially. Dr. Poma's extensive background positions Calidi Biotherapeutics to potentially accelerate its research and development efforts in the competitive biotechnology landscape.
The leadership change underscores Calidi's commitment to maintaining a dynamic and forward-thinking approach to medical innovation. By bringing in a seasoned executive with deep industry expertise, the company signals its intent to strengthen its position in developing advanced therapeutic solutions.
